Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 4312
Gene Symbol: MMP1
MMP1
0.010 Biomarker disease BEFREE <b>Result:</b> The effective adhesion rate of MB<sub>MMP-1</sub> and MB<sub>IgG</sub> to HEp-2 was 298.42 ± 16.57 versus 12.38 ± 3.26 bubbles/per field <i>in vitro</i> experiment, which shows a significant difference (<i>P</i> < 0.01). 31275143 2019
Entrez Id: 3033
Gene Symbol: HADH
HADH
0.010 GeneticVariation disease BEFREE 3'UTR variant of HADH, rs221347 and rs4975616, located within known cancer risk locus 5p15.33, were specific to risk of laryngeal cancer. 28582492 2017
Entrez Id: 2946
Gene Symbol: GSTM2
GSTM2
0.040 GeneticVariation disease BEFREE Larynx cancer risk in relation to glutathione S-transferase M1 and T1 genotypes and tobacco smoking. 9456238 1998
Entrez Id: 27306
Gene Symbol: HPGDS
HPGDS
0.030 GeneticVariation disease BEFREE Glutathione S-transferase GSTM3 and GSTP1 genotypes and larynx cancer risk. 10067818 1999
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation disease BEFREE P53 tumor suppressor gene mutations in laryngeal cancer and in recurrent disease following radiation therapy. 11978553 2002
Entrez Id: 4501
Gene Symbol: MT1X
MT1X
0.010 Biomarker disease BEFREE MT I/II transcript was observed in HOK16B, which was further elevated in HOK16B-Bap-T. Retrospective analysis showed that high immunoreactivity to MT I/II in surgically resected laryngeal cancer specimen correlated with increased frequency of recurrence within 2 years of surgery. 12616185 2003
Entrez Id: 4498
Gene Symbol: MT1JP
MT1JP
0.010 Biomarker disease BEFREE MT I/II transcript was observed in HOK16B, which was further elevated in HOK16B-Bap-T. Retrospective analysis showed that high immunoreactivity to MT I/II in surgically resected laryngeal cancer specimen correlated with increased frequency of recurrence within 2 years of surgery. 12616185 2003
Entrez Id: 4499
Gene Symbol: MT1M
MT1M
0.010 Biomarker disease BEFREE MT I/II transcript was observed in HOK16B, which was further elevated in HOK16B-Bap-T. Retrospective analysis showed that high immunoreactivity to MT I/II in surgically resected laryngeal cancer specimen correlated with increased frequency of recurrence within 2 years of surgery. 12616185 2003
Entrez Id: 4489
Gene Symbol: MT1A
MT1A
0.010 Biomarker disease BEFREE MT I/II transcript was observed in HOK16B, which was further elevated in HOK16B-Bap-T. Retrospective analysis showed that high immunoreactivity to MT I/II in surgically resected laryngeal cancer specimen correlated with increased frequency of recurrence within 2 years of surgery. 12616185 2003
Entrez Id: 4493
Gene Symbol: MT1E
MT1E
0.010 Biomarker disease BEFREE MT I/II transcript was observed in HOK16B, which was further elevated in HOK16B-Bap-T. Retrospective analysis showed that high immunoreactivity to MT I/II in surgically resected laryngeal cancer specimen correlated with increased frequency of recurrence within 2 years of surgery. 12616185 2003
Entrez Id: 4495
Gene Symbol: MT1G
MT1G
0.010 Biomarker disease BEFREE MT I/II transcript was observed in HOK16B, which was further elevated in HOK16B-Bap-T. Retrospective analysis showed that high immunoreactivity to MT I/II in surgically resected laryngeal cancer specimen correlated with increased frequency of recurrence within 2 years of surgery. 12616185 2003
Entrez Id: 4496
Gene Symbol: MT1H
MT1H
0.010 Biomarker disease BEFREE MT I/II transcript was observed in HOK16B, which was further elevated in HOK16B-Bap-T. Retrospective analysis showed that high immunoreactivity to MT I/II in surgically resected laryngeal cancer specimen correlated with increased frequency of recurrence within 2 years of surgery. 12616185 2003
Entrez Id: 4543
Gene Symbol: MTNR1A
MTNR1A
0.010 Biomarker disease BEFREE MT I/II transcript was observed in HOK16B, which was further elevated in HOK16B-Bap-T. Retrospective analysis showed that high immunoreactivity to MT I/II in surgically resected laryngeal cancer specimen correlated with increased frequency of recurrence within 2 years of surgery. 12616185 2003
Entrez Id: 4490
Gene Symbol: MT1B
MT1B
0.010 Biomarker disease BEFREE MT I/II transcript was observed in HOK16B, which was further elevated in HOK16B-Bap-T. Retrospective analysis showed that high immunoreactivity to MT I/II in surgically resected laryngeal cancer specimen correlated with increased frequency of recurrence within 2 years of surgery. 12616185 2003
Entrez Id: 56052
Gene Symbol: ALG1
ALG1
0.010 Biomarker disease BEFREE MT I/II transcript was observed in HOK16B, which was further elevated in HOK16B-Bap-T. Retrospective analysis showed that high immunoreactivity to MT I/II in surgically resected laryngeal cancer specimen correlated with increased frequency of recurrence within 2 years of surgery. 12616185 2003
Entrez Id: 4494
Gene Symbol: MT1F
MT1F
0.010 Biomarker disease BEFREE MT I/II transcript was observed in HOK16B, which was further elevated in HOK16B-Bap-T. Retrospective analysis showed that high immunoreactivity to MT I/II in surgically resected laryngeal cancer specimen correlated with increased frequency of recurrence within 2 years of surgery. 12616185 2003
Entrez Id: 4500
Gene Symbol: MT1L
MT1L
0.010 Biomarker disease BEFREE MT I/II transcript was observed in HOK16B, which was further elevated in HOK16B-Bap-T. Retrospective analysis showed that high immunoreactivity to MT I/II in surgically resected laryngeal cancer specimen correlated with increased frequency of recurrence within 2 years of surgery. 12616185 2003
Entrez Id: 644314
Gene Symbol: MT1IP
MT1IP
0.010 Biomarker disease BEFREE MT I/II transcript was observed in HOK16B, which was further elevated in HOK16B-Bap-T. Retrospective analysis showed that high immunoreactivity to MT I/II in surgically resected laryngeal cancer specimen correlated with increased frequency of recurrence within 2 years of surgery. 12616185 2003
Entrez Id: 864
Gene Symbol: RUNX3
RUNX3
0.010 PosttranslationalModification disease BEFREE RUNX3 methylation was also detected in hepatocellular carcinomas (73%, n=48), larynx cancers (62%, n=37), lung cancers (46%, n=24), breast cancers (25%, n=25), prostate cancers (23%, n=44), endometrial cancers (12.5%, n=24), colon cancers (4.9%, n=61) and uterine cervical cancers (2.5%, n=40), showing that RUNX3 methylation is not restricted to gastric cancer. 14968123 2004
Entrez Id: 595
Gene Symbol: CCND1
CCND1
0.090 Biomarker disease BEFREE CCND1 and MLH1 seem functionally interconnected in regard to chromosomal imbalances in larynx cancer. 17201183 2007
Entrez Id: 3956
Gene Symbol: LGALS1
LGALS1
0.010 Biomarker disease BEFREE Galectin-1 has been found to modulate lymphocyte invasion in inflammation and to be involved in angiogenesis in models, thus prompting examination of its clinical relevance in laryngeal cancer. 19331133 2009
Entrez Id: 960
Gene Symbol: CD44
CD44
0.030 Biomarker disease BEFREE CD44 was the only biological factor tested which significantly correlated with response to radiotherapy in early stage larynx cancer patients, both at the mRNA and protein levels. 20837694 2010
Entrez Id: 10327
Gene Symbol: AKR1A1
AKR1A1
0.020 GeneticVariation disease BEFREE Alcohol-dehydrogenase (ADH1B) Arg48His polymorphism in Basque Country patients with oral and laryngeal cancer: preliminary study. 21378355 2011
Entrez Id: 1508
Gene Symbol: CTSB
CTSB
0.010 Biomarker disease BEFREE Cathepsin B may be used as a promising therapeutic target in the treatment of laryngeal cancer. 21667036 2011
Entrez Id: 648
Gene Symbol: BMI1
BMI1
0.030 Biomarker disease BEFREE BMI1'S maintenance of the proliferative capacity of laryngeal cancer stem cells. 21755556 2011